Phase II Randomized Study of Whole Brain Radiation Therapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG
This randomized phase II trial studies how well whole-brain radiation therapy or
stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients
with breast cancer that has too many of a protein called human epidermal growth factor
receptor 2 (HER2) on its cells and has spread to the brain. Radiation therapy uses high
energy x rays to kill tumour cells and shrink tumours. Stereotactic radiosurgery is a
specialized radiation therapy that delivers a single, high dose of radiation directly to the
tumour and may kill more tumour cells and cause less damage to normal tissue. Lapatinib
ditosylate may stop the growth of tumour cells by blocking some of the enzymes needed for
cell growth. It is not yet known whether whole-brain radiation therapy or stereotactic
radiosurgery together with lapatinib ditosylate is an effective treatment for brain
metastasis from breast cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society